Rofecoxib: A review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis

Drugs

Volumn 61, Issue 6, 2001, Pages 833-865

  Matheson, A J ^a   Figgitt, D P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; INDOMETACIN; MELOXICAM; MORPHINE DERIVATIVE; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; ROFECOXIB;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG COST; DRUG EFFICACY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSMENORRHEA; HEADACHE; HUMAN; KIDNEY FUNCTION; NAUSEA; NONHUMAN; OSTEOARTHRITIS; PAIN; PHYSICIAN ATTITUDE; POSTOPERATIVE PAIN; RHEUMATOID ARTHRITIS; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TOOTH PAIN; ULCEROGENESIS; VERTIGO;

EID: 0034980484     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161060-00019     Document Type: Article

References (74)

1. Scientific rationale for specific inhibition of COX-2
2. COX-2 selective nonsteroidal anti-inflammatory drugs: Do they really offer any advantages?
3. Cyclooxygenase-2 selective inhibitors
4. Mechanism of action of antiinflammatory drugs
5. Selective cyclooxygenase-2 inhibitors
6. Celecoxib: A review of its use in osteoarthritis, rheumatoid arthritis and acute pain
7. The cyclooxygenase-2 inhibitors: Safety and effectiveness
8. Rofecoxib
9. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
10. Rofecoxib [Vioxx, MK-0966; 4-(4-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles
11. Demonstration of specific COX-2 inhibition by MK-966 in humans with supratherapeutic doses [abstract no. PII-69]
12. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans
13. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen
14. COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: Double blind crossover study comparing rofecoxib with placebo and indomethacin
15. A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects
16. Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production
17. A new cyclooxygenase-2 inhibitor rofecoxib (VIOXX®), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers
18. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers
19. AHFS Drug Information. Rofecoxib. American College of Health System Pharmacists, Inc.
20. Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans
21. Pharmacokinetics of rofecoxib in mild to moderate hepatic insufficiency (HI)
22. Effect of rofecoxib in the pharmacokinetics of digoxin in healthy volunteers
23. Influence of a selective cyclooxygenase-2 inhibitor, MK-0966, on ethinyl estradiol and norethindrone (NET) serum concentrations
24. Influence of a selective cyclooxygenase-2 (COX-2) inhibitor, rofecoxib (MK-0966, Vioxx™), on prednisone and prednisolone plasma concentrations [abstract no 856]
25. No effect of rofecoxib up to 50mg daily on methotrexate plasma concentrations
26. Effect of specific COX-2 inhibition in osteoarthritis of the knee: A 6 week double blind, placebo controlled pilot study of rofecoxib
27. Clinical response of OA patients who use acetaminophen when randomized to rofecoxib or ibuprofen
28. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis
29. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs
30. A clinical trial comparing rofecoxib to celecoxib and acetaminophen in the treatment of osteoarthritis (OA): Early efficacy results
31. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip
32. The effects of rofecoxib and diclofenac on knee osteoarthritis (OA) articular cartilage: The results from one-year prospective clinical trials [abstract no. OP-082]
33. Evaluation of onset of action of rofecoxib, naproxen and nabumetone in patients with osteoarthritis (OA)
34. A multicenter, randomized, controlled thal to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis
35. Ex vivo assay of COX-2 inhibition predicts analgesic efficacy in post-surgical dental pain with MK-966
36. MK-966 versus naproxen sodium 550 mg in post-surgical dental pain [abstract no. PI-7]
37. Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in postdental surgery pain: A randomized, controlled trial
38. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: A randomized, placebo- and activecomparator-controlled clinical trial
39. Are the biologic and clinical effects of the COX-2-specific inhibitors an advance compared with the effects of traditional NSAIDs?
40. Efficacy of single-dose and multidose rofecoxib in the treatment of post-orthopedic surgery pain
41. Postoperative analgesic effects of celecoxib or rofecoxib after spinal fusion surgery
42. Preoperative oral rofecoxib does not decrease postoperative pain after radical prostatectomy. A prospective, randomized, double-blind, placebo-controlled trial [abstract 941]
43. The COX-2 specific inhibitor, MK-0966, is effective in the treatment of primary dysmenorrhea
44. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: A randomized controlled trial
45. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis
46. A two-part placebo and active comparator-controlled study of rofecoxib in the treatment of rheumatoid arthritis (RA): One-year experience
47. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
48. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
49. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis
50. COX-2 inhibitors
51. Fewer gastrointestinal protective agents, procedures and hospitalizations with rofecoxib vs. naproxen in the VIGOR (Vioxx GI outcomes research) study
52. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specfic inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
53. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial
54. Tolerability profiles of rofecoxib (Vioxx®) and Arthrotec®
55. Rofecoxib, a specific inhibitor COX-2, was not associated with allergic reactions in patients with a history of sulfur-allergy
56. Economic implications of comparing rofecoxib to NSAIDs in the treatment of osteoarthritis in Ontario, Canada
57. COX-1-sparing NSAIDs - Is the enthusiasm justified?
58. Arthritis and the aging population: Projections of arthritis prevalence in Canada 1991 to 2031
59. The increasing impact of arthritis on public health
60. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States
61. Recommendations for the medical management of osteoarthritis of the hip and knee
62. Guidelines for the medical management of osteoarthritis: Part II osteoarthritis of the knee
63. Guidelines for the management of rheumatoid arthritis
64. EULAR recommendations for the management of knee osteoarthritis: Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)
65. From prostaglandin replacement to specific COX-2 inhibition: A critical appraisal
66. Cyclooxygenase 2 selective inhibitors: Panacea or flash in the pan?
67. Primary dysmenorrhoea
68. Five studies on ibuprofen for postsurgical dental pain
69. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis